Neuren Pharmaceuticals Limited (ASX:NEU)
Australia
· Delayed Price · Currency is AUD 11.68
-0.67 (-5.43%)
At close: Mar 9, 2026
Neuren Pharmaceuticals Revenue
In the year 2025, Neuren Pharmaceuticals had annual revenue of 64.65M AUD, down -70.18%. Neuren Pharmaceuticals had revenue of 36.37M in the half year ending December 31, 2025, a decrease of -78.48%.
Revenue
64.65M
Revenue Growth
-70.18%
P/S Ratio
22.87
Revenue / Employee
8.08M
Employees
8
Market Cap
1.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 64.65M | -152.18M | -70.18% |
| Dec 31, 2024 | 216.83M | -15.11M | -6.51% |
| Dec 31, 2023 | 231.94M | 216.53M | 1,404.46% |
| Dec 31, 2022 | 15.42M | 12.22M | 382.23% |
| Dec 31, 2021 | 3.20M | 2.48M | 345.89% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PYC Therapeutics | 20.56M |
| Clarity Pharmaceuticals | 10.58M |
| Mesoblast | 98.02M |
| Opthea | -20.12K |
| Telix Pharmaceuticals | 1.21B |
| Immutep | 7.92M |
| Clinuvel Pharmaceuticals | 96.30M |
| Racura Oncology | 3.48M |
Neuren Pharmaceuticals News
- 6 days ago - Neuren Partner Acadia To Seek EMA Re-Examination After CHMP Rejects Trofinetide For Rett Syndrome - Nasdaq
- 25 days ago - Neuren Pharmaceuticals Limited (NURPF) Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 Transcript - Seeking Alpha